Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Ovarian Neoplasms 33Breast Neoplasms 26Triple Negative Breast Neoplasms 17Prostatic Neoplasms 16Fallopian Tube Neoplasms 11Neoplasms 9Fanconi Anemia, Complementation Group D1 7Endometrial Neoplasms 7Pancreatic Neoplasms 6Glioma 6Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Sarcoma 5Neoplasm Metastasis 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Lymphoma, Non-Hodgkin 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Osteosarcoma 3Lung Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinosarcoma 3Carcinoma, Renal Cell 3Wilms Tumor 2

Interventions

atezolizumab 3Docetaxel 3pembrolizumab 2olaparib 2lenvatinib 2Leucovorin 2Irinotecan 2Immune Checkpoint Inhibitors 2Fluorouracil 2Filgrastim 2Capecitabine 2zolbetuximab 1tomivosertib 1spartalizumab 1somatostatin receptor 2 1pralsetinib 1pegylated granulocyte colony-stimulating factor 1necitumumab 1motesanib diphosphate 1ipatasertib 1inavolisib 1entrectinib 1ensartinib 1dapagliflozin 1cobimetinib 1cemiplimab 1cat's claw extract 1balugrastim 1anlotinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumors × olaparib × Clear all
NCT04123366 2026-04-22

MK-7339-007

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
300 enrolled
Other solid neoplasm

Solid Tumors

NCT07018622 2026-03-11

DAPA-ARMOR

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase 2 Recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡